Core Viewpoint - Crispr Therapeutics AG, in partnership with Vertex, has received approvals for its CRISPR/Cas9 gene editing therapy, Casgevy, targeting Sickle Cell Disease and transfusion-dependent beta thalassemia, but has yet to report revenue figures from the drug due to the complex treatment process [2][3][7]. Treatment and Revenue Potential - Casgevy is priced at approximately $2.2 million per treatment, with around 20 patients having cells collected as of mid-July, suggesting potential revenue of at least $44 million for the first half of 2024 [7]. - The number of authorized treatment centers (ATCs) has increased from 9 at launch to 35, with a target of 75, indicating a growing capacity to treat patients [7][9]. - If each ATC can treat 30 patients annually, potential annual revenues for Crispr Therapeutics could reach $1.98 billion if all 75 centers are operational [7][9]. Efficacy and Market Position - Over 90% of patients treated with Casgevy in pivotal studies remain transfusion-independent and free from vaso-occlusive crises, highlighting the therapy's effectiveness [8]. - The competitive landscape includes other therapies, but Casgevy offers a permanent cure, differentiating it from alternatives like Pfizer's Oxbryta [8][9]. Future Developments - Crispr Therapeutics is exploring ways to reduce the preconditioning burden for patients, potentially expanding the addressable patient population significantly [9][10]. - The company is also working on in vivo therapies that could eliminate the need for complex treatment processes, which may enhance its market position [9][10]. Pipeline and Financial Health - Crispr Therapeutics has a robust pipeline, including allogeneic therapies and in vivo programs, which could significantly increase its market cap if successful [12]. - Despite a net loss of $126.4 million in Q2, the company maintains a strong cash position of approximately $1.7 billion, ensuring a secure funding runway for ongoing research and development [12]. Investment Outlook - The current market cap of Crispr Therapeutics is $4.2 billion, with expectations that revenues from Casgevy could exceed $1 billion annually by 2025 or 2026, potentially increasing the market cap to over $10 billion [14].

CRISPR Therapeutics (CRSP) incurred a loss of $1.49 per share in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of $1.37. In the year-ago period, the company had incurred a loss of 98 cents per share. The company's total revenues, though negligible, were entirely from grant revenues, which were $0.5 million in the second quarter. The reported figure significantly missed the Zacks Consensus Estimate of $8 million. In the year-ago quarter, the company generated collabo ...

CASGEVY Approval and Efficacy - CASGEVY, the first-ever approved CRISPR-based gene-editing therapy, has been approved in the United States, European Union, Great Britain, Kingdom of Saudi Arabia, and Kingdom of Bahrain for treating severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older[51] - CASGEVY has shown efficacy as a potential one-time functional cure for severe SCD and TDT, with safety data consistent with autologous stem cell transplant and myeloablative conditioning[51] Next-Generation CAR T Cell Therapies - The company is advancing next-generation CAR T cell therapies, including CTX112 (targeting CD19) and CTX131 (targeting CD70), which show significantly higher CAR T cell expansion and functional persistence compared to first-generation candidates[53] - CTX112 is being investigated in clinical trials for relapsed or refractory CD19-positive B-cell malignancies and systemic lupus erythematosus, with early studies showing long-lasting remissions in autoimmune indications[54] - CTX131 is being developed for solid tumors and hematologic malignancies, including T cell lymphomas, with ongoing clinical trials assessing its safety and efficacy[55] In Vivo Gene Editing Programs - The company's in vivo gene editing programs, CTX310 and CTX320, target cardiovascular disease by disrupting ANGPTL3 and LPA genes, respectively, with up to 20% of the global population having elevated Lp(a) levels[57] Type 1 Diabetes Therapy Development - CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for type 1 diabetes, is in a Phase 1/2 clinical trial, with the company receiving $170 million in upfront and milestone payments from Vertex in 2023[59] Next-Generation Editing Modalities - The company's CRISPR-X research team is developing next-generation editing modalities, including whole gene correction and insertion without requiring homology-directed repair or viral delivery of DNA[60] Strategic Partnerships and Collaborations - Strategic partnerships with Vertex, ViaCyte, and Bayer are accelerating the development of gene-editing therapies, with Vertex co-developing and co-commercializing CASGEVY and licensing CRISPR/Cas9 technology for diabetes[61] - Additional collaborations with companies like Nkarta, Capsida Biotherapeutics, and MaxCyte support the company's hematopoietic stem cell, immuno-oncology, and in vivo programs[62] Financial Performance and Expenses - The company has not generated any revenue from product sales and does not expect to do so in the near future. Revenue for the three and six months ended June 30, 2024 was not material, while revenue for the same periods in 2023 was $70.0 million and $170.0 million, respectively, primarily from an upfront payment and a research milestone achieved with Vertex[64][71][76] - Research and development expenses for the three months ended June 30, 2024 were $80.2 million, a decrease of $21.4 million compared to $101.6 million in the same period in 2023, primarily due to reduced external research and manufacturing costs[72] - General and administrative expenses for the three months ended June 30, 2024 were $19.5 million, slightly higher than the $19.0 million in the same period in 2023[73] - Collaboration expense, net, for the three months ended June 30, 2024 was $52.1 million, an increase of $7.5 million compared to $44.6 million in the same period in 2023, primarily due to commercial and manufacturing costs related to the CASGEVY program with Vertex[74] - Net loss for the three months ended June 30, 2024 was $126.4 million, compared to a net loss of $77.7 million in the same period in 2023, driven by higher collaboration expenses and lower revenue[70] - For the six months ended June 30, 2024, the company reported a net loss of $243.0 million, compared to a net loss of $130.8 million in the same period in 2023, primarily due to a significant decrease in collaboration revenue and increased collaboration expenses[75] - Research and development expenses decreased by $45.2 million to $156.3 million for the six months ended June 30, 2024, primarily due to reduced external R&D costs ($34.3 million), facility-related expenses ($8.2 million), and employee-related expenses ($4.0 million)[77] - General and administrative expenses decreased by $4.0 million to $37.4 million for the six months ended June 30, 2024, driven by lower employee-related and consulting expenses[78] - Collaboration expense, net, increased by $12.3 million to $99.1 million for the six months ended June 30, 2024, primarily due to commercial and manufacturing costs related to the CASGEVY program[79] - Other income increased by $19.8 million to $50.9 million for the six months ended June 30, 2024, mainly due to higher interest income from cash, cash equivalents, and marketable securities[80] Cash and Financial Position - The company had $2,012.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024, with $154.1 million held outside the U.S. and an accumulated deficit of $1,242.7 million[81] - Net cash provided by operating activities increased by $138.6 million to $14.2 million for the six months ended June 30, 2024, driven by a $270.0 million increase in accounts receivable[86] - Net cash used in investing activities was $224.7 million for the six months ended June 30, 2024, compared to $334.8 million provided in the same period in 2023, due to increased purchases of marketable securities[87] - Net cash provided by financing activities was $305.5 million for the six months ended June 30, 2024, primarily from the sale of $280.0 million in common shares to institutional investors[88] - The company expects its existing cash, cash equivalents, and marketable securities to fund operations for at least the next 24 months, based on current R&D plans and timing expectations[84] - The company's cash, cash equivalents, and marketable securities of $2,012.8 million are primarily invested in U.S. treasury securities, government agency securities, corporate bonds, and commercial paper, with minimal exposure to interest rate risk[91] Legal Proceedings - No material adverse legal proceedings currently pending against the company[96] - No significant developments in previously disclosed legal proceedings[96] Future Outlook and Expectations - The company expects to continue incurring significant research and development expenses as it progresses its current development programs, adds new programs, and prepares regulatory filings[66] - The company has a history of recurring losses and expects to continue incurring losses for the foreseeable future, with expenses likely to increase as it advances its research and development activities[63] - The company has the option to defer specified costs on the CASGEVY program in excess of $110.3 million for the years ended December 31, 2022, 2023, and 2024, with deferred amounts payable as an offset against future profitability of the program[68] - The company's revenue recognition for the three and six months ended June 30, 2023 was primarily related to an upfront payment from Vertex and a research milestone achieved in the second quarter of 2023[64][71][76]

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) a ...

Another stock from the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals (ALNY) , is soon expected to post loss of $0.71 per share for the quarter ended June 2024. This estimate indicates a yearover-year change of +67.9%. Revenues for the quarter are expected to be $452.73 million, up 42% from the year-ago quarter. The market expects CRISPR Therapeutics AG (CRSP) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. ...

The company's shares have seen a decrease of 2.93% over the last month, not keeping up with the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96%. CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.51 per share and revenue of $89.43 million. These results would represent year-over-year changes of -184.02% and -75.91%, respectively. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have d ...

We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports second-quarter 2024 results next month. The Zacks Consensus Estimate for CRSP's total revenues currently stands at $8.39 million. CRISPR Therapeutics has a positive earnings surprise history. The company beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 117.78%. In the last reported quarter, CRSP's earnings beat estimates by 12.27%. Other Stocks to Consider Amgen Inc. (AMGN) has an Ear ...

California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Prosper Junior Bakiny (CRISPR Therapeutics): It's always an important milestone for a clinical-stage biotech to launch its first product. That's what happened with CRISPR Therapeutics last year. The gene-editing specialist earned approval for Casgevy, developed in collaboration with Vertex Pharmaceutic ...

Other purposes of gene editing include making crops more resistant to viruses and bacteria and better able to cope with extremes of heat and cold caused by global warming. One day, gene editing could alter people's DNA and prevent certain diseases from developing. In some circles, gene editing is controversial, though the science behind it is widely viewed as legitimate. Source: rafapress / Shutterstock.com Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals is a more mature and established biotech company ...

CRISPR Therapeutics AG (CRSP) shares ended the last trading session 9.2% higher at $62.75. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7% loss over the past four weeks. This rise in share price is attributable to positive investor expectations for the company's sole-marketed product Casgevy which received marketing approval in late 2023/early 2024. Marketed in partnership with Vertex Pharmaceuticals, Casgevy is ...